Therapeutic Targets of Bufalin on Renal Carcinoma and Mechanisms: Experimental Validation of Network Pharmacology Analysis | Zendy

Lei Zhang | Zendy; Yiming Pan | Zendy; Lu-Yao Wang | Zendy; Wanzhu Zhao | Zendy; Shaocheng Yang | Zendy; Xue-Fang Sun | Zendy; Xin Guan | Zendy; Bing Yan | Zendy

Open Access

Therapeutic Targets of Bufalin on Renal Carcinoma and Mechanisms: Experimental Validation of Network Pharmacology Analysis

Author(s) -

Lei Zhang,

Yiming Pan,

Lu-Yao Wang,

Wanzhu Zhao,

Shaocheng Yang,

Xue-Fang Sun,

Xin Guan,

Bing Yan

Publication year - 2022

Publication title -

evidence-based complementary and alternative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.552

H-Index - 90

eISSN - 1741-4288

pISSN - 1741-427X

DOI - 10.1155/2022/5469795

Subject(s) - bufalin , kegg , signal transduction , computational biology , biological pathway , biology , gene , gene expression , transcriptome , microbiology and biotechnology , biochemistry , apoptosis

The possible targets underlying the activity of bufalin on renal cell carcinoma (RCC) were investigated using network pharmacology and experimental approaches. PharmMapper and other databases were explored for predicting the bufalin targets and RCC-related targets. Finally, the enriched pathways and the targets were analyzed by the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathway enrichment analyses. Furthermore, in vitro cell experiments were used to verify bufalin activation of AKT and MAPK signaling pathways in human mesangial cells. The therapeutic targets related to bufalin were identified via 35 intersecting targets. GO analysis identified 29 molecular functions, 16 cellular components, and 91 biological processes. KEGG pathway annotation identified 15 signal transduction pathways and 4 tumor-related pathways.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research